M&A Deal Summary

LabGenomics Acquires IMD

On October 25, 2024, LabGenomics acquired life science company IMD

Acquisition Highlights
  • This is LabGenomics’ 2nd transaction in the Life Science sector.
  • This is LabGenomics’ 2nd transaction in the United States.
  • This is LabGenomics’ 1st transaction in California.

M&A Deal Summary

Date 2024-10-25
Target IMD
Sector Life Science
Buyer(s) LabGenomics
Deal Type Add-on Acquisition

Target

IMD

Berkeley, California, United States
IMD specializes in molecular diagnostics and provides advanced technology and infrastructure to support community-based pathology and oncology practices, particularly in the field of cancer management. IMD is based in Berkeley, California.

Search 214,356 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

LabGenomics

Seongnam-si, South Korea

Category Company
Founded 2002
Sector Life Science
Revenue 85.9B KRW (2024)
DESCRIPTION

LabGenomics is a healthcare company specializing in molecular diagnostics. LabGenomics offers several cancer tests, including ‘BRCA1/BRCA2,’ ‘comprehensive genetic cancer panel,’ and ‘OTD-Solid’ test. LabGenomics was formed in 2002 and is based in Seongnam-si, South Korea.


DEAL STATS #
Overall 2 of 2
Sector: Life Science M&A 2 of 2
Type: Add-on Acquisition M&A Deals 2 of 2
State: California M&A 1 of 1
Country: United States M&A 2 of 2
Year: 2024 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-09-05 Qdx Pathology Services

Edison, New Jersey, United States

Qdx Pathology Services provides personalized laboratory services, as well as a full range of ancillary support and practice management solutions. Qdx Pathology Services is based in Edison, New Jersey.

Buy -